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Abstract
In the present work, a copper-tirapazamine (TPZ) nanocomplex [Cu(TPZ)2] was synthesized as a selective hypoxia-targeted therapy. The 
nanocomplex revealed a crystalline form, and exhibited higher lipophilicity, compared to TPZ. Furthermore, its stability was confirmed in 
different media, with minimum dissociation in serum (~20% up to 72 h). In contrast to other hypoxia-targeted agents, our intrinsically 
fluorescent nanocomplex offered an invaluable tool to monitor its cellular uptake and intracellular distribution under both normoxia and 
hypoxia. The conferred higher cellular uptake of the nanocomplex, especially under hypoxia, and its biocompatible reductive potential 
resulted in superior hypoxia selectivity in two prostate cancer (PC) cell lines. More promisingly, the nanocomplex showed higher potency in 
three-dimensional tumor spheroids, compared to TPZ, due to its slower metabolism, and probably deeper penetration in tumor spheroids. 
Interestingly, the nuclear localization of the intact nanocomplex, combined with its higher DNA binding affinity, as evidenced by the DNA 
binding assay, resulted in significant S- phase cell-cycle arrest, followed by apoptosis in three-dimensional spheroids model. In conclusion, 
the presented findings suggested that Cu(TPZ)2 nanocomplex can be a promising hypoxia-targeted therapeutic, which could  potentiate the 
efficacy of existing chemo- and radiotherapy in PC.
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Introduction
Bio-reductive hypoxic activated pro-drugs (HAP) have been 
widely exploited as selective cytotoxic compounds, driven by 
low oxygen conditions, showing promise as novel cancer 
therapeutics 1, 2. Several N-oxide compounds have been 
proposed as potential candidates, with some progressing into 
clinical trials. Of particular interest is the hypoxic cytotoxin 3-
amino-1, 2, 4-benzotriazine-1, 4-dioxide (tirapazamine – TPZ) 
which exhibits 30-300 times higher toxicity to cells in low 
oxygen conditions, compared to other cytotoxic agents 3-5. TPZ 
is the most advanced bioreductive pro-drug in clinical trials, 
owing to its one-electron reduction pathway, and hypoxia 
selective DNA damaging action 3. Nonetheless, its clinical 
efficacy  has been limited by its poor cellular uptake, restricted 
tissue diffusion and rapid metabolism 4. 
Copper has attracted special attention over the last years as a 
promising metal coordinate to target cancer hypoxia. The low 
molecular weight, lipophilicity and planar structure of its 
complexes allow rapid cellular internalization and targeting of 
hypoxia 6, 7. It also possesses unique properties conferred by 
the variety of coordination geometries, metal-ligand 
interactions and redox activity that allows functionalization of 
ligands and effective cellular targeting (DNA, proteins, enzymes 
and redox pathways) 8. Its unique electronic structure, and cell 
compatible reduction potential (E0′ (Cu2+/Cu+) allows it to play 
a fundamental role in cellular growth and proliferation 9. The 
coordination of metal ions to hypoxic cytotoxins is an 
interesting strategy to develop novel hypoxia-targeted 
therapeutics. These complexes have been exploited 
therapeutically with different organic ligands 9, and in 
radiodiagnosis or radiotherapy 10. Extensive work by J. 
Dearling, J. Holland and J. Dilworth has provided detailed 
analysis on the therapeutic and hypoxia imaging applications of 
copper-complexes 7, 9-11. 
Copper-based complexes have now been widely exploited for 
anti-cancer therapy, and their potential thoroughly reviewed 
elsewhere 12. Most of these complexes presented improved 
chemical characteristics compared to the free ligand, 
contributing to their increased hypoxic uptake, thus more 
selective and/or potent biological activity 11, 13-15. Particular 
attention has been drawn to Cu(II) complexes including N,N-
diimine ligands, thiosemicarbazones, bis(thiosemicarbazones), 
schiff base assemblies and pyridine-N-oxides and their ability 
to induce DNA damage, via binding or intercalation 12. 
Although this is the primary mechanism of action, new cellular 
targets such as DNA topoisomerases 16, the proteasome 
complex 17, 18, endoplasmic reticulum 19 and lysosome 20, have 
also become interesting pathways of cell death for copper-
complex mediated therapeutics, highlighting the versatility and 
potency of these metal therapeutics.
Lin and Ho 21 were the first to demonstrate the potential use of 
TPZ with copper to enhance DNA damaging in cancer cells. 
Next, they prepared a radioactive TPZ-copper complex for 
targeted cancer therapy  22.  These studies did not report the 
basic characterization of the complex, which, in our opinion, is 
considered essential to further understand its biological 
relevance. Furthermore, data regarding its potential use as a 
hypoxia cytotoxic agent in more complexed hypoxia models is 
still warranted. In the present work, we aimed to synthesize 
and characterize a cupric-TPZ complex (abbreviated in the text 
as Cu(TPZ)2). We sought to understand how complexation with 
copper could modulate TPZ’s physicochemical properties (e.g, 
optical properties, solubility, and lipophilicity), and its 
biological activity. Ideally, this Cu(TPZ)2 complex should 
maintain or improve TPZ hypoxia selectivity and potency while 
providing an innovative metal-complex strategy for hypoxia 
therapeutics. Therefore, it was essential to determine the 
selectivity and potency of this complex vs TPZ alone. Using 
both 2-dimensional (2D), and 3-dimensional (3D) prostate 
cancer models, the uptake and cytotoxicity of Cu(TPZ)2 was 
determined in this study. Overall, Cu(TPZ)2 complex should 
overcome some of the TPZ shortcomings in vitro, which could 




4-(2 Hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES), 
sodium chloride (NaCl), phosphate buffer saline (PBS) tablets, 
tirapazamine (≥98% HPLC), copper(II) chloride (97%), methanol 
(HPLC grade) and Universal MALDI Matrix [1:1, 2,5-
dihydroxybenzoic acid (DHB): α-cyano-4-hydrocinnamic acid] 
were obtained from Sigma (UK). Laboratory reagent dimethyl 
sulfoxide (DMSO), chloroform (HPLC grade, stabilized with 
amylene), methanol (HPLC grade), and ethanol (absolute, 
99.8%) were bought from Thermo Fisher Scientific (UK). Milli-Q 
water was prepared using a water purification system 
(Millipore Corp., Bedford, MA, USA). All organic solvents were 
of analytical grade, unless otherwise stated. All starting 
materials were commercially available research grade 
chemicals and were used without further purification.
Preparation of Cu(TPZ)2 complexes
Two equivalents of TPZ (13.2 mg, 0.074 mmol) were added 
slowly to a total of 5 mL stirred ethanolic solution of CuCl2 (5 
mg, 0.037 mmol), resulting in the formation of a deep red 
precipitate. Following overnight stirring, the dark red 
precipitate was isolated, and washed with small volumes of 
ethanol by centrifugation at 5000 xg for 10 min, until a 
colorless supernatant was obtained. The red complex was then 
left to dry under vacuum at 25°C, and resuspended in DMSO 
until complete solubility was obtained (~2.5 mM stock 
solution). The complex was then sterile filtered through 0.2 µm 
membrane filter. The stoichiometry of the compound was 
[Cu(TPZ)2], and the yield ~70% (11 mg, 0.026 mmol). The 
results of the elemental analysis (%) obtained with a Carlo Erba 
EA 1108 analyzer were: (C14H10CuN8O4) Found/Calcd.: C, 
39.85/40.32; N, 25.66/26.87; H, 2.39/2.21. IR (ATR) analysis: 
(ν/cm−1) - (νN–H2), 3360-3311; (δN–H2), 1570; (νN → O), 1358; 
(νC-N/νC-C), 1111, 1165, 1215. MALDI-MS: m/z (%) [Cu(TPZ)2-
H]+, Found/Calcd (%): 418.0199/418.0202 (100). Full details of 
TPZ and Cu(TPZ)2 characterization can be found in the 
experimental section of the supplementary information.
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Biological studies
In vitro cytotoxicity of TPZ and Cu(TPZ)2 complex in PCa 
monolayers
LNCap (CRL-1740™) and C4-2B cells were purchased from 
ATCC® and  MD Anderson Cancer Center (Texas, USA), 
respectively. The cells were maintained in Advanced RPMI-
1640 (1x) medium supplemented with 10% heat inactivated 
FBS, 1% penicillin/streptomycin and 1% GlutaMax (200 mM). 
Cells were maintained in Corning® CellBIND® 75 cm3 canted-
neck tissue culture flasks (Fisher Scientific, UK) to enhance cell 
adherence. For normoxic condition, cell cultures were 
maintained in a humidified incubator at 37°C in 5% CO2/95% 
air. For hypoxia treatment, cells were placed in a hypoxic 
chamber (Incubator chamber Billups Rothenberg Inc., MIC-101) 
with a mixture of 1% O2, 5% CO2, and 94% N2 (BOC, UK). 
Hypoxia was validated using the CYTO-ID® Hypoxia/Oxidative 
Stress Detection kit (Enzo Life Sciences. UK) according to the 
manufacturer manual 23. 
Cell culture media and drug stock solutions were pre-purged 
with the hypoxic gas mixture to minimize oxygen fluctuations. 
The cytotoxicity of TPZ and Cu(TPZ)2 was determined using the 
resazurin assay, as previously described 24. Resorufin 
fluorescence intensity (FI) was measured using a BMG 
microplate reader (FLUOstar Omega, BMG Labtec) at 544 nm 
excitation and 590 nm emission. The average percentage cell 
viability was calculated by normalizing the values to the 
untreated cells, using the following formula:  
                                             𝐂ell Viability (%) =
FItreated
FIcontrol × 100
Uptake and cellular localization of TPZ and Cu(TPZ)2 complex
For quantitative uptake studies, confluent C4-2B cells were 
harvested by trypsinization and seeded onto pre-coated poly-
D-lysine (100 µg/mL) 24 flat-bottom well plates (Triplered, UK) 
at 5 × 104 cells/well. The cells were incubated overnight under 
either normoxia or hypoxia to allow adherence. Next, cells 
were incubated with free TPZ or its complex (100 µM 
equivalent TPZ) at 37 °C for 1, 4, 8 and 24 h to assess uptake. At 
specific time periods, the medium was removed and the wells 
were washed (3X) with 200 µl of cold PBS to remove any free 
drug. After that, cells were harvested by trypsinization and 
pelleted by centrifugation (500 x g, 10 mins). The pellet was 
resupended in 200 µL of DMSO (to guarantee solubility of 
released drug) and cells were then lysed by mechanical 
disruption using a bath sonicator for about 15 min (Ultrasound 
cleaning baths, USC, VWR). This ensured full disruption of cell 
membrane and intracellular organelles. The fluorescence 
intensity of each sample well was measured using a microplate 
reader (FLUOstar Omega, BMG Labtec) at 485 nm excitation 
and 590 nm emission. The percentage of drug uptake was 
calculated by dividing the fluorescence of each well by the 
fluorescence of the initial drug concentration used. 
For fluorescence microscopy, C4-2B cells were seeded at 5 × 
104/well onto pre-coated poly-D-lysine (100 µg/mL) Coverslips 
(Fisher Scientific, UK), placed in 24 well assay plates (Triplered, 
UK) and left to adhere overnight at 37 °C under normoxia or 
hypoxia. Next, the cells were incubated with TPZ or its complex 
for 1, 4, 8 and 24 h, under both normoxia or 1% hypoxia. Cells 
were then washed with cold PBS and fixed with 4% PFA at 
room temperature for 20 min, then washed (3X) with cold PBS. 
The nuclei were stained with Hoechst 33258 (5 µg/mL) (Sigma, 
UK) for 30 min at 37°C. Finally, the coverslips were washed (3X) 
with PBS, and mounted using ProLong™ Gold Antifade 
mounting media (Fisher Scientific, UK). Images were obtained 
using a Zeiss Axioplan 2 epifluorescence Axiovision 4.1.8 
software. Images were processed and analysed using ImageJ 
(NIH, Bethesda, MD, USA: http://imagej.nih.gov/ij). For each 
endpoint, duplicates of two independent experiments (n=2) 
resulted in the analysis of over 50 cells. For some experimental 
conditions a z-stack with 1.75 µm intervals was generated 
using the Apotome to form a 3D reconstruction and evaluate 
co-localization via orthogonal projections. All images were 
acquired with a 10x/0.45 air objective and Axiovision 4.1.8 
software, processed and analysed using ImageJ (NIH, Bethesda, 
MD, USA: http://imagej.nih.gov/ij).
Analysis of Cu(TPZ)2 metabolism using FTIR and NMR 
C4-2B cells were seeded on pre-coated poly-D-lysine (100 
µg/mL) at 5 × 104/well in 24 well assay plates (Triplered, UK) 
and left to adhere overnight at 37 °C under hypoxia. Next, the 
cells were incubated with TPZ in its free or complex form (100 
µM equivalent TPZ) for 1, 4, 8 and 24 h, under 1% hypoxia 
using a hypoxic chamber (Ruskinn Invivo2 400 Hypoxia 
Workstation). At specific time periods, the medium was 
removed and the wells were washed (3X) with PBS to remove 
any free drug, and cells were lysed with 200 µL of RIPA buffer. 
Cell lysate samples were stored at -20 °C until further FTIR and 
NMR analysis.   
200 µL of cell lysates was diluted in 200 µL D2O (Fisher, UK) and 
probed by nuclear magnetic resonance (NMR). The Spectra 
were recorded at 297 K, on an ultra-shield 400 instrument (1H 
frequency: 400 MHz; Bruker, Germany). Then, all the samples 
were dried and were dissolved in 400 µL CDCl3 in presence of 
Tetramethyl silane (TMS) and run at the same conditions. 
Finally, the samples were dried and dissolved in DMSO in the 
presence of TMS. The samples were analyzed using IR 
spectroscopy (Spectrum Two FTIR, Perkin Elmer, USA) over the 
range 650–4000 cm-1 with a resolution of 4 cm-1.
In vitro cytotoxicity of TPZ and Cu(TPZ)2 in C4-2B spheroids
C4-2B spheroids were cultured and characterized as described 
in the supporting information. Five days post spheroid seeding, 
100 µL of media was carefully removed and replaced with pre-
diluted fixed concentrations of TPZ in free and complexed form 
(TPZ equivalent: 0.002 up to 20 µM). Spheroids were treated 
for 48, 72 and 96 h using 10% DMSO as a positive control. 
Spheroids were carefully washed with PBS 1x and replenished 
with fresh media or pre-treated with EDTA (5 mM) for 30 min, 
with shaking (70 rpm) to ensure resazurin penetration and 
reliable quantification 24. Resazurin solution (20 μl) was then 
added to each well and the spheroids were further incubated 
overnight, at 37°C to determine cell viability. To complement 
the viability assay, representative spheroid images were taken 
to monitor spheroid size changes before and after treatment. 
The average percentage cell viability for each drug 
concentration was expressed as mean ± S.D of six replicates of 












































































Please do not adjust margins
Please do not adjust margins
three independent experiments (≥18 spheroids, n≥2) and 
calculated by normalizing the FI values to the untreated cells. 
Dose-response curves were generated, where possible, and the 
IC50 values for drug inhibition were determined by nonlinear 
regression analysis of the data fit to a four-parameter equation 
(GraphPad Prism version 7, La Jolla California USA 
www.graphpad.com).
Cell cycle and apoptosis analysis using Flow Cytometry
C4-2B spheroids were cultured at a density of 5 × 103 cells/well, 
as described above and on day 5 of growth, were treated with 
2 and 20 µM (equivalent TPZ content) in free and copper-
complexed form. Untreated spheroids were used for 
population gating to avoid the undesired noises from debris 
and singlet gating to minimize debris and cell aggregates. 72 
h post-treatment, spheroids were harvested, using a 1 mL pre-
cut micropipette tip, into 1.5 mL micro centrifuge tubes (Fisher 
Scientific, UK) and centrifuged at 500 × g for 5 min, to sediment 
the spheroids. The cells were then washed 3× with cold PBS, 
with repeated centrifugation and resuspended in 100 µL of 
PBS. Thereafter, a single cell suspension was formed by 
mechanical dissociation, using a micropipette, and cells were 
fixed in 70% ethanol for at least 1 h, on ice. To achieve this, 400 
µL of ice-cold 70% ethanol was added dropwise to each 
sample, while vortexing to ensure complete fixation and avoid 
cell clumping. Cells were then washed 3× with PBS (first spin at 
800 × g, 10 min, to recover all cells) and the cell pellet was 
resuspended in 0.5 mL of propidium iodide/RNase solution 
(FxCycle™ Solution, Molecular Probes, UK). The samples were 
incubated for 30 min at room temperature, protected from 
light and further analysed, without washing, by flow cytometry 
using a Becton Dickinson CytoFLEX (Beckman Coulter, UK). Cell 
doublets were separated from single cells in G2/M phase using 
pulse-width/pulse-area signal. At least 10,000 cells were 
acquired in a histogram and cell cycle data were exported as 
FSC files and analysed using FlowJo software. Each data 
measurement was made up from at least ten pooled spheroids, 
repeating the whole procedure independently two times (n=2). 
Results were expressed as mean ± S.D, after population 
deconvolution, peak integration and calculation of population 
percentage.
DNA binding studies
The interaction between Cu(TPZ)2 (25 µM) and calf-thymus 
DNA (CT-DNA) was analysed by UV/Vis spectroscopy. The CT-
DNA stock solution, was prepared in Tris-buffer (containing 5 
mM Tris-HCl and 50 mM NaCl at pH 7.2). The UV absorbance at 
260 and 280 nm of the CT-DNA gave a ratio of 1.84, indicating 
that DNA was sufficiently free of protein contamination. DNA 
stock concentration (8.71 mM) was determined 
spectrophotometrically at 260 nm, by using the molar 
extinction coefficient value of 6600 M-1 cm-1 25.
Cu(TPZ)2 (25 µM) solutions were also prepared in Tris-buffer, 
where red dispersion was observed, indicating good dispersion 
of the complex in this buffer. We further performed electronic 
absorption titrations, which were carried out with a constant 
concentration of the copper(II) complex (25 µM) and varying 
concentrations of CT-DNA (0–500 µM) in Tris-buffer. The 
complex and DNA solutions were incubated at 37 °C for 24 h. 
Subsequently, the spectra were recorded using a UV/Vis 
spectrophotometer at ambient temperature. Solutions of free 
CT-DNA (namely in the absence of copper compound) at the 
corresponding concentrations (0–500 µM) were used as blanks 
before recording the absorption band of each sample. The 
titrations of the corresponding concentration of TPZ (50 µM) 
were also performed, with varying concentrations of CT-DNA 
(0–500 µM). Solvent samples without DNA or drug were used 
as baseline references. The results were presented as mean 
absorbance of triplicate samples of two independent 
experiments (n=2).
The intrinsic binding constant (Κb) for the interaction of 
Cu(TPZ)2 with CT-DNA was calculated using the following 
equation:
[DNA]
εa -  εf
=  
[DNA]
εb -  εf
 +
1
Κb (εb -  εf)
where εa, εf and εb correspond to, the apparent molar 
extinction coefficient - Aobsd/[Cu], the molar extinction 
coefficient for the free Cu(TPZ)2, and the molar extinction 
coefficient for the Cu(TPZ)2 in the fully bound form, 
respectively. By plotting [DNA]/( εa- εf) vs [DNA], Κb was  then 
determined by calculating the ratio of the slope to the  
intercept.
Statistical analysis
Data was presented as mean ± SD. Two-way Analysis of 
variance (ANOVA) and Bonferroni multiple comparisons post-
hoc test was performed when three or more groups of data 
were analysed. P-values < 0.05 were considered significant and 
statistical differences amongst groups was appropriately 
denoted in the figure captions. The IC50 values for inhibition 
were determined by nonlinear regression analysis of the data 
fit to a four-parameter equation. All analyses and graphs were 
generated using GraphPad Prism version 7.0 (GraphPad 
Software, La Jolla California USA, www.graphpad.com). 
Results
Cu(TPZ)2 synthesis and characterization
In this study, Cu(TPZ)2 complex was prepared by mixing TPZ 
with CuCl2 salt in an ethanolic solution (Figure. 1A). The red 
precipitate was collected, and its chemical structure was 
confirmed using elemental analysis, FTIR (Figure. S1), and mass 
spectrometry (MS) (Figure. S2). The relevant physicochemical 
properties (molecular mass, pKa and logP values) of TPZ 26 and 
Cu(TPZ)2 27  were summarized in Figure. 1B. Based on the 
literature, Cu(TPZ)2 complex exhibited a biocompatible 
reductive potential (-0.75V vs. Ag/AgCl), which was more 
electronegative than that presented by TPZ (-0.65V vs. 
Ag/AgCl), suggesting superior selectivity under hypoxia 10, 19, 20, 
28. 
The morphology and the structure of the isolated Cu(TPZ)2 
complex were also analyzed using TEM and X-ray powder 
diffraction (XRD), respectively. Due to the higher hydrophobic 
nature of the complex (solubility ~2.5mM in DMSO), some 
intermolecular interactions occurred at high concentrations, 
resulting in highly organized nanostructures in more polar 
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solvents (e.g. ethanol). Interestingly. TEM examination 
revealed that the complex morphology was concentration-
dependent, where needle-like structures (300-400 nm in 
length) were present at high concentrations (2 mM), and tiny 
and homogenous spherical nanoparticles (3-4 nm in diameter) 
were observed at lower concentrations (20 µM) (Figure. 1C), 
similar to the concentration range used in this study (20 µM). 
The large needle structures possibly result from π → π stacking 
and van der Waals interaction between molecules 14, 17, which 
strongly agrees with the proposed 3D structure (Figure. 1A). 
Single-crystal X-ray diffraction measurement was not possible 
to perform due to the small size of the complex crystals, 
however, the XRD result confirmed that the complex is in the 
crystalline form, with the following diffraction reflections 8.3º, 
10.9º, 13.4º, 15.6º, 18.9º, 25.6º and 28.7º (Figure. S4). All the 
complex characterization results are described in detail in the 
supporting information.
Cu(TPZ)2 stability and dissociation in different media
TPZ complexation was further confirmed using UV-Vis 
spectrophotometry. Both free and complexed TPZ showed 
similar optical properties in DMSO, with two characteristic 
absorption peaks at λmax 280 nm and 500 nm (Figure. 1D). In 
HBS TPZ presented a less intense band at λmax 280 nm and a 
more intense band at λmax 462 nm (Figure. 1E), arisen from the 
π → π* transitions in the phenyl group and π → π* transitions 
from the pyridine-N-Oxide, respectively. Cu(TPZ)2 maintained a 
ligand centered band at λmax 280 nm and a broad absorption 
band in the visible region at  500-600 nm, which is 
characteristic for copper (II) d-d transition band (band I: 
dxy,yz→dx2-y2 ) 29. The optical properties in different aqueous 
media were also studied, as described in the supporting 
information (Figure. S5).
To fully understand the dissociation mechanism of the 
complex, a simple titration study was performed by diluting the 
formed complex in aqueous buffers with a wide range of pH 
(Figure. 1F). An immediate color change was observed by 
decreasing the pH from 7.4 to 5. This was confirmed by a 
visible shift in the complex absorption (555 nm and 595 nm) to 
a lower wavelength (462 nm), indicating the dissociation of the 
complex at lower pH. A single sigmoidal curve was fitted to the 
absorbance at 462 nm and plotted against pH, providing a pKa 
value of 2.7 (Figure. S5D), comparable to that obtained before 
for TPZ 27. Furthermore, the stability of the complex was 
assessed in 50% serum, where minimum dissociation was 
evidenced (~20% up to 72 h) (Figure. S6), indicating high 
stability of the complex under physiological conditions. It is 
possible that a small number of Cu(TPZ)2  molecules could have 
undergone copper-translocation via serum albumin47, leading 
to free TPZ liberation. 
Cellular uptake and metabolic analysis of intrinsically 
fluorescent Cu(TPZ)2 complex
Poole et al.  previously reported weak fluorescence of TPZ in 
solutions 30. This agrees with our findings, where TPZ was 
fluorescent a wide range of aqueous media (Figure. S7A), 
except at pH 12.5 (Figure. S7B) 30. Our current results showed 
that complexing TPZ to copper did not affect TPZ fluorescence 
emission in DMSO (Figure 2A, left). On the other hand, a 
significant enhancement in intensity was observed in HBS 
buffer pH 7.4 (Figure. 2A, right), with a 50-nm red shift upon 
coordination to the metal center. Interestingly, as the complex 
dissociated at low pH, a two-fold reduction in the fluorescence 
intensities was observed, reaching the same level of free TPZ. 
This strongly indicates that the fluorescent enhancement was 
metal-induced (Figure. S7C). Despite the strong quenching 
capacity of Cu(II), such fluorescence enhancement following 
copper complexation was previously reported 28.
Encouraged by the intrinsic fluorescence of the complex, and 
its high serum stability, we further monitored its cellular 
localization and accumulation under normoxia (21% O2) and 1% 
hypoxia, where the latter was validated using a hypoxia marker 
(Figure. S8). Representative images were then taken at 1, 4, 8 
and 24 h under normoxia (Figure 2B, left) and hypoxia (Figure 
2B, right), which showed the cellular accumulation of Cu(TPZ)2 
(green fluorescence) in C4-2B cells. Interestingly, the results 
depicted a rapid uptake (1 h) of the complex, with strong green 
fluorescent signals in the cytosol and perinuclear region, under 
both normoxia and 1% hypoxia. Furthermore, some images 
evidenced nuclear localization of the intact fluorescent 
complex, presented as diffuse green signals in the nucleus 
(Figure 2B) or as punctate signals (Figure. S9). At 4 h, the 
appearance of bright green punctate structures (depicted by 
white arrows), particularly in hypoxic conditions, suggested 
that copper complex can also accumulate in lysosomal 
compartments or autophagic structures 6, 10, 11, 14, however, the 
exact mechanism of the complex internalization should be 
confirmed . After 8 h, the fluorescent signals were clearly 
lower, suggesting complex efflux, dissociation or metabolism, 
as we further confirmed. A slight increase in fluorescence was 
observed after 24 h, possibly due to reoxidation of a small 
number of Cu(TPZ)2 molecules via copper recycling pools. 
Further studies are required to investigate this observation.
TPZ’s weak fluorescence was not reliable to evaluate its cellular 
uptake and localization under the same conditions (Figure. 
S10). Therefore, we developed a quantitative method to assess 
the complex uptake overtime. We compared the total uptake 
of TPZ and Cu(TPZ)2, up to 24 h, under both normoxia and 1% 
hypoxia conditions (Figure. 2C). As evidenced before 5, TPZ 
showed low cellular uptake, with no significant differences 
under both normoxia and hypoxia. On the other hand, Cu(TPZ)2 
showed a significant improvement in cellular uptake, under 
normoxia (4 h, p<0.001; 8 h, p<0.01 and 24 h, p<0.0001) and 
hypoxia (4 h, p<0.0001; 8 h, p<0.05 and 24 h, p<0.0001), 
compared to TPZ (Figure. 2C). These observations could be 
attributed to the higher lipophilicity of the complex (LogP 2.88) 
compared to TPZ (LogP -0.31).  More importantly and in line 
with previous reports 10, 13, 14, the complex demonstrated 
selective hypoxia uptake at 4 h with higher uptake efficiency 
compared to normoxia (p <0.001). The bioreductive cycle in the 
lysosome (Ered -0.75), could be responsible for this high 
intracellular accumulation, with decreased complex efflux 
under hypoxia 15. The full mechanism underlining this hypoxia 
selectivity is detailed in the discussion section. Furthermore, 
the slight decrease in cell uptake at 8 h, could be attributed to 
complex dissociation in acidic compartments, such as 
lysosomes, with consequent loss of fluorescence intensity, 
which agrees with the fluorescent imaging and previous results 
(Figure S7C). 
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Drug metabolism could be responsible for the decreased 
intracellular concentrations of the complex. To verify this, we 
assessed the metabolism of TPZ and the complex following cell 
internalization, under hypoxia, using non-fluorescent-based 
techniques, namely FTIR and NMR. Our qualitative FTIR results, 
revealed a fast metabolism of TPZ, in contrast to the complex, 
where free TPZ was metabolized and an intermediate was 
formed within 1 h of cell internalization (Figure. S11). This fast 
TPZ metabolism is in agreement with the literature 31. On the 
other hand, neither free TPZ, nor its intermediate metabolite 
was detected in the cell lysate samples incubated for 1 h with 
the complex (Figure. S12), re-emphasising the stability of the 
complex intracellularly, and its slow metabolism, respectively. 
Between 4 and 24 h similar metabolites were present in all 
samples. Moreover, as anticipated, the metabolite levels in the 
TPZ samples were much higher compared to cells incubated 
with the complex (Figure. 3C), indicating slower metabolism of 
the complex, as confirmed by NMR. These quantitative results 
showed that the levels of the complex metabolites, in contrast 
to free TPZ, fluctuated over time, with the highest level 
detected after 4 h. The metabolism decreased slightly around 8 
h, before increasing again after 24 h (Figure. 3C). It is worth 
mentioning that the complex was present in the cell lysate 
(pellet) samples (Figure. 3B), but could not be detected using 
NMR, since it was precipitated from the supernatant due to a 
solubility issue. Interestingly, these results could justify the loss 
of fluorescence signal at 8 h (Figure. 2B& 2C), followed by 
some signal recovery at 24 h. Several in vitro studies reported 
TPZ benzotriazine radical and mono-N-oxide (SR4317) as major 
TPZ metabolites 32, however, in presence of DNA, identifying 
the exact metabolites becomes more challenging, since the 
interaction of TPZ benzotriazine radicals with the DNA results 
in DNA damage, and different products are formed 33. The 
latter observation could possibly explain the unreported 
metabolite peaks detected by NMR (Figure. 3), however, the 
exact metabolites formed in our study remain to be identified. 
Hypoxia selectivity of Cu(TPZ)2 complex in PCa cells
To assess hypoxia selectivity, the cytotoxicity of free TPZ and 
Cu(TPZ)2 complex was studied under normoxia (21% O2) and 
1% hypoxia in two prostate cancer (PCa) cell lines. The 
inhibitory concentrations (IC50) were determined under both 
conditions and used to calculate the hypoxia cytotoxicity ratio 
(HCR, IC50 normoxia/IC50 hypoxia), which expresses hypoxia 
selectivity. The IC50 and HCR values obtained in the PCa cell 
lines are summarized in Table S1.
Our results demonstrated that the cytotoxicity of TPZ and its 
complex was cell-, and time-dependent (Figure. 4A). C4-2B, an 
androgen-independent 34, derived bone metastatic PCa cell 
model, exhibited high sensitivity to the hypoxia pro-drugs, with 
clear dose-response shifts to the left at 1% hypoxia (Figure. 
S13). The effect was especially pronounced in terms of hypoxia 
selectivity, confirmed by the overall increased HCR values of 
Cu(TPZ)2, compared to TPZ (Table S1). The HCR values were 
consistently higher for the complex and achieved exceptional 
selectivity for this cell line at 72 h post-treatment (HCR: 72 h, 
~70). Furthermore, the cytotoxic effects under normoxia 
revealed a significant 2.03, 2.61 and 3.78-fold increase in IC50 
(at 48, 72 and 96 h, respectively) for Cu(TPZ)2 compared to TPZ 
alone (Figure. 4A, top panel). More promisingly, enhanced 
potentiation of the complex under hypoxia (IC50: 1.61 ± 1.0), 
compared to TPZ (IC50: 2.831 ± 1.04 µM) was also obtained at 
72 h time-point, confirming the augmented selectivity and 
therapeutic potency of the complex in C4-2B. Similar finding 
were obtained in LNCap, an androgen-dependent PC cells 
(Figure. 4A, bottom panel), which showed high sensitivity to 
both agents under hypoxia (Figure. S14), and superior hypoxia 
selectivity with the Cu(TPZ)2 (Table S1). LNCap cells have been 
shown to readapt under hypoxia, through a metabolic shift, 
which may sensitize these cells to hypoxia-selective treatments 
35. It is therefore plausible to argue that oxygenation is only 
one parameter influencing the activity of these drugs and may 
well be a simplistic view of their MoA. All cell lines were 
cultured under the same conditions, yet they exhibit 
differences in toxicity and selectivity. Hypoxia adaptation and 
the reductive capacity of these cell lines will certainly influence 
the sensitivity to TPZ and Cu(TPZ)2. 
Potency of Cu(TPZ)2 against C4-2B tumor spheroids
In order to validate the previous cytotoxicity data in 
monolayers, 3D hypoxia models of C4-2B, were developed 
(Figure.  5A & Figures. S15-S16), and C4-2B spheroids were 
incubated with TPZ or Cu(TPZ)2 up to 96 h. The resazurin assay 
was used to quantify cell viability, and spheroids imaging was 
used to monitor cell morphology post-treatment (Figure. S17). 
As expected, TPZ (Figure 5B) was less potent in spheroids 
(Table S2) compared to C4-2B monolayers (Table S1).  
Furthermore, TPZ toxicity in 3D cultures was not dose- or time- 
dependent (IC50: 48h, 35.17 ± 1.17 µM; 72h, 26.21 ± 1.18 µM, 
96h: 36.02 ± 1.89 µM) (Figure. 5B & Table S2). This data 
indicated that TPZ’s toxicity is possibly restricted to the 
spheroid surface layer, since it is metabolized too rapidly 26, 31, 
36-39, as we previously showed. On the other hand, Cu(TPZ)2 
showed dose and time-dependent cytotoxicity in C4-2B 
spheroids (Figure 5C and Table S2) (IC50: 48h, 41.78 ± 5.67 µM; 
72h, 25.58 ± 3.78 µM, 96h: 13.33 ± 1.43 µM). The results 
correlated well with the different metabolic rates of the 
complex compared to TPZ (Figure. 3). At 48 h, spheroids were 
slightly more resistant to Cu(TPZ)2 (IC50: 41.78 ± 5.67 µM) 
compared to TPZ (IC50: 35.17 ± 1.17 µM), but reached a 
pronounced therapeutic activity at 96h (Cu(TPZ)2, IC50: 13.33 ± 
1.43 µM; TPZ, IC50: 36.02 ± 1.89 µM, p<0.0001). 
Furthermore, in order to determine the cellular responses 
after TPZ and Cu(TPZ)2 drug testing, cell cycle and apoptosis 
analyses were carried out. 5-days post seeding, C4-2B 
spheroids were treated for 72 h with 20 and 2 µM equivalent 
TPZ in both free and complex forms. Cell cycle histograms 
were generated to evaluate cell cycle distribution (Figure. 
S18). Interestingly, data showed marked arrest in S-phase 
population, followed by decrease in G1 for Cu(TPZ)2 treated 
spheroids at both 10 (p<0.05) and 1 µM (p<0.01), compared to 
untreated or TPZ-treated spheroids (Figure. 5D). Furthermore, 
this significant S-phase arrest was accompanied by increased 
propidium iodide (PI)-positive apoptotic cells following 
Cu(TPZ)2 (10 µM) treatment, compared to untreated and TPZ 
groups (Figure. 5E). 
Enhanced DNA binding of Cu(TPZ)2 
The cell cycle analysis results suggested that TPZ cytotoxicity in 
C4-2B spheroids may be mediated by non-selective 
mitochondrial and ROS induced cell death 40, while Cu(TPZ)2 
may exert an increased DNA selective cytotoxic activity. To 
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confirm the latter, UV–Vis absorption spectra of free TPZ were 
recorded in the absence and presence of increasing 
concentrations of CT-DNA solution (Figure. 5F). No spectral 
changes were observed, indicating that TPZ did not interact 
with DNA in the absence of its radical counterpart 41. On the 
other hand, Cu(TPZ)2 (Figure. 5G) showed a significant 
hyperchromic effect in the entire spectrum, with a small 
bathocromatic shift, which indicates a non-intercalative 
binding mode through DNA groove binding, resulting in 
damaging of the DNA double-helical structure 25. The DNA 
binding constant (Kb 0.18 × 102 M-1) (Figure. 5G, inset), was in 
agreement with other DNA groove binding agents and much 
lower than standard DNA intercalators 42. This indicates that 
Cu(TPZ)2 complex has a moderate DNA binding capacity, 
possibly through DNA groove binding, but intercalation cannot 
be ruled out, supporting previous evidence on the enhanced 
DNA damaging capacity of this complex 21. Further studies on 
DNA viscosity, damage and ROS production can further 
elucidate the mechanisms of action of this cupric-TPZ complex.
Discussion
Cancer hypoxia has been highly associated with treatment 
resistance and metastasis; therefore, a wide range of hypoxia-
activated prodrugs have been developed to targeting hypoxia 1, 
2. TPZ is the most advanced bioreductive pro-drug in clinical 
trials, however, its clinical efficacy  has been limited by its poor 
cellular uptake, restricted tissue diffusion and rapid 
metabolism 4. Several structure-activity relationship (SAR) 
studies with TPZ analogues have provided substantive 
correlation between specific substituents (and their position) 
with improved pharmacological outcomes 43. Moreover, the 
use of transition metal complexes has shown to be a 
particularly suitable strategy to modify existing pro-drugs and 
develop a new biologically active molecule with improved 
hypoxia activity 7. Copper(II) complexes have shown to 
coordinate well with 1,2,4-benzotriazine 1,4-di-N-oxides 44, 45, 
generating prodrug complexes that are stable under 
physiological conditions, but become kinetically labile with 
changes in the redox status or pH of the environment. Two 
studies reported TPZ-copper complex as a hypoxia-selective 
agent in 2D culture 21,22, however, these studies neither 
demonstrated any correlation between the complex 
characteristics and its biological activity, nor assessed  its 
activity in 3D hypoxia culture models. In our work, we have 
revealed unreported characteristics of the complex, such as its 
lipophilicity (LogP 2.88), particulate nature, slow metabolism, 
as well as its superior intrinsic fluorescence, enabling its 
cellular trafficking and quantification under normaxia and 
hypoxia. Collectively, with the published reductive potential of 
the complex, we have been able, and for the first time, to 
provide better understanding of the biological activity of the 
complex in 2D and 3D hypoxia PC models. 
TPZ has been shown to possess a pH-dependent cytotoxicity 46, 
where the slightly acidic microenvironment (pH 6.0) 
dramatically increased its aerobic cytotoxicity, thus 
contributing to the observed clinical side-effects (muscle 
cramping, peripheral neuropathy, and intestinal symptoms) 4, 5. 
Interestingly, our results suggest that the high pH stability of 
the complex could minimize TPZ systemic toxicity.  Studies 
have also shown that the reductive hypoxic environment plays 
a key role in determining the dissociation rate of metal-
complexes. Previous reports have shown that copper trans-
chelation could occur with serum albumin 47, or thiol-rich 
molecules (glutathione, cysteine and ascorbate), which are 
capable of reducing these complexes intracellularly 27. The 
former was not observed with our complex since high serum 
stability was observed. Nevertheless, previous data 21 showed 
that TPZ can compete with glutathione for copper, but not 
EDTA, once again confirming the stability of Cu(TPZ)2. All these 
findings are important from a biological point of view, and the 
data presented here suggested that Cu(TPZ)2 may be 
dissociated via a pH-dependent mechanism, intracellular thiol-
mediated reduction, but not by serum albumin trans-chelation 
emphasising its stability in the blood followings its systemic 
administration.
Previous reports, have shown high potentiation of TPZ under 
different hypoxia levels (HCR: 30-300) that was cell-line 
dependent 4. Factors such as p53 status , expression of 
reductive enzymes, e.g. cytochrome c P450 48, CA-IX, acidic 
microenvironment  and of homologous recombination proteins 
(XRCC2, Rad51D, BRCA1 and BRCA2)  have been shown to 
influence TPZ sensitivity and cannot be ruled out 48. 
Interestingly, the PC cell lines used here showed differential 
metabolic profiles under hypoxia and aggressiveness is marked 
by defects in DNA repair mechanisms, p53 status and increased 
basal ROS levels 35. Previously, Adsule et al.18, developed a 
potent quinoline-2-carboxaldehyde copper complex, which 
inhibited proteasome activity in PC-3 and LNCaP cells (IC50 of 4 
and 3.2 µM, respectively). However, studies were only carried 
out under normoxic conditions, not specifying any hypoxia 
selectivity. In this work, Cu(TPZ)2 complex exhibited low 
cytotoxicity under normoxia with IC50 above ca. 50 µM for all 
cell lines, while under 1% hypoxia IC50 values ranged from 
moderate (>10 µM) to potent activity (<10 µM). Cu(TPZ)2 
showed higher potency, compared to TPZ, in C4-2B, but higher 
selectivity was observed in both cells tested. The HCR heatmap 
results (Figure. 4B) showed a moderate effect at 48 h, for both 
drugs, against LNCap, and C4-2B. HCR values were consistently 
higher for Cu(TPZ)2 (>10) in LNCap and C4-2B, compared to 
TPZ, with outstanding selectivity in C4-2B after 72 h (HCR of ca. 
70), confirming the potential of this complex as HAPs in PC. 
This superior selectivity is attributed to the higher 
electronegativity of the complex compared to TPZ. Most 
research surrounding hypoxia selectivity is based on the unique 
cellular trapping mechanism proposed for Cu(ATSM) 49. This 
copper(II) complex has been widely exploited in vitro and in 
vivo, due to its enhanced accumulation in hypoxic tissues. 
Generally, complexes with reduction potential more 
electronegative than -0.57 V vs. Ag/AgCl, display optimum 
hypoxia selectivity. Upon reduction, under hypoxia, these 
copper(II) complexes will partially dissociate into an 
intermediary copper(I) compound, which is more labile and 
eventually undergoes complete dissociation, liberating the free 
ligand 50. Copper(I) is then bound to specific binding proteins 
and chaperones such as Ctr1 and Atx1, respectively, which 
mediate the copper cellular pool 50. Whilst, under normoxia, 
the intermediary copper(I) compound will be reversibly oxidize 
to its copper(II) counterpart and diffuse out of the cells. 
Although the redox-properties provide reliable gold-standard 
in hypoxia selectivity, other factors influencing reduction rate 
should not be ruled out. Indeed, the degree of expression of 
intracellular reductases has shown to influence dissociation, as 
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well as other biological reductants such as ascorbate, thiols or 
NADP(H), as discussed previously. 
TPZ’s limited diffusion and incapacity to reach the relevant 
hypoxic cells, in tumor models have been previously reported 
26, 31, 36-39. To overcome these limitations, analogues with 
increased lipophilicity (due to removal of H-bond donor of the 
3NH2 group), comparable to that of Cu(TPZ)2, showed 
pronounced uptake, selectivity and tissue diffusion,  26, 38, 43. In 
agreement with these studies, the superior potency of the 
complex in C4-2B spheroids, compared to free TPZ, as 
confirmed  by cell viability and cell cycle analysis, could be 
attributed to the high lipophilicity of the complex in 
combination with its good pH and serum stability, slow 
metabolism, and high electronegative potential (-0.75 V), 
resulting in decreased early onset toxicity to the outer layer of 
the spheroid and possible free ligand back-diffusion from the 
inner spheroid to induce high cell toxicity throughout the 
spheroid environment 51. Furthermore, its higher DNA binding 
as we demonstrated, and reported by others 21 could 
contribute to higher potency.  However, the exact mechanism 
of toxicity in spheroids has yet to be investigated.  
Conclusions
We successfully presented the synthesis and extensive 
characterization of a nano-sized Cu(TPZ)2 complex that 
improved on TPZ’s physicochemical properties and its hypoxia 
selectivity in PC. The synthesized copper-complex, exhibited 
high LogP, increased biocompatible redox-potential, slow 
metabolism, and high DNA binding, compared to TPZ. The 
intrinsic fluorescence of the complex enabled studying its 
cellular uptake, concluding on its significant hypoxia selective 
uptake and accumulation in the perinuclear area and in 
intracellular vesicles. In addition, our results reported for the 
first time the biological activity of Cu(TPZ)2 complex in 3D 
hypoxia models. Interestingly, Cu(TPZ)2 complex exhibited 
excellent hypoxia selectivity compared to TPZ, particularly in 
the castrate-resistant C4-2B PC monolayers. Furthermore, the 
improved structural activity of the complex correlated well 
with its enhanced efficacy in C4-2B spheroids. Further studies 
are still warranted to determine the Cu(TPZ)2 exact mechanism 
of action in vitro. Finally, the limited solubility of the complex 
could be overcome using clinically relevant delivery systems, 
such as liposomes, to assess its therapeutic efficacy in vivo.
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Figures and captions
Figure 1. Synthesis and characterization of hypoxia-selective Cu(TPZ)2 complex. A) Schematic representation of the 
synthesis protocol of Cu(TPZ)2 complex in ethanol (Inset: optimised structure); B) A summary of main physicochemical 
properties of TPZ and Cu(TPZ)2; C) TEM images of Cu(TPZ)2 at high (2 mM) and low (20 µM) concentrations, depicting a 
concentration-dependent, self-aggregation of the complex in ethanol; D) Absorbance spectra of TPZ (10 µM, solid line) and 
Cu(TPZ)2 (5 µM, dotted line) in DMSO; E) Absorbance spectra of TPZ (60 µM, solid line) and Cu(TPZ)2 (30 µM, dotted line) in 
HBS; and F) Absorbance of Cu(TPZ)2 (50 µM) at different pH values, illustrating a pH-dependent dissociation of Cu(TPZ)2. Inset 
shows a yellow color change of TPZ to a dark red solution upon complexation and vice-versa, upon dissociation.
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Figure 2. Intrinsic fluorescence, uptake and cellular localization of Cu(TPZ)2 complex in C4-2B prostate cancer cells. A) 
Fluorescence spectra of TPZ and Cu(TPZ)2 diluted in DMSO (left) and HBS (right) (DMSO: λexc/λem 490/600 nm; HBS:  λexc/λem 
450/570 nm (TPZ) and λexc/λem 500/600 nm (Cu(TPZ)2). B) Qualitative uptake of Cu(TPZ)2 (100 µM equivalent TPZ) at 1, 4, 8 
and 24 h under normoxia and 1% hypoxia. The white arrows depict intense green puncta signals, suggesting accumulation of 
the complex in intracellular vesicles. The signals were more prominent under hypoxic conditions and in the perinuclear area. 
Images are representative of at least 50 cells of two independent experiments (n=2). Green channel: Cu(TPZ)2 treated cells; 
Blue channel: nuclei stained with Hoechst 33258. Scale bars, 20 μm. C) Quantitative uptake of TPZ and Cu(TPZ)2 in C4-2B cells. 
Cells were incubated with 25 µM equivalent TPZ, and the cellular uptake was determined at 1, 4, 8 and 24 h under normoxia 
and 1% hypoxia. Fluorescence was measured at λexc/λem 485/590 nm in DMSO. Results were expressed as mean ± SD for 
triplicates of three independent experiments (n=3). Statistical analysis using Two-way ANOVA multiple comparison with 
Bonferroni Post-test (GraphPad Prism version 7.0, GraphPad Software Inc., La Jolla, CA, USA) was performed to compare 
uptake of TPZ vs Cu(TPZ)2: (**p≤0.01, ***p≤0.001 and ****p≤0.0001, comparing drugs under normoxia; #p≤0.05, and 
####p≤0.0001, comparing drugs under hypoxia; and $$$p≤0.001, comparing Cu(TPZ)2 under hypoxia and normoxia.
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Figure 3: 1H-NMR in CDCl3 of C4-2B cell lysates. Cells were incubated under 1% hypoxia with (A) TPZ and (B) Cu(TPZ)2 for 
different duration (1, 4 ,8 ,24 h). Untreated cells were used as a control. Samples were prepared for NMR analysis as 
described in the methods section. TPZ (1 mg/ 400 µl) was also analysed (peaks a,b,c), however the complex was not soluble 
in CDCl3 and no peaks were detected. The photograph (inset in Figure. 3B) represents the pinkish cell lysate pellets, indicating 
the presence of Cu(TPZ)2 in the cell lysate samples. The main sharp peak (*) represents the solvent. (C) peak heights for the 
TPZ and Cu(TPZ)2 metabolites.
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Figure 4.  IC50 values of Cu(TPZ)2 complex and TPZ incubated with two PCa cells under normoxia and 1% hypoxia. A) C4-2B 
(top panel) and LNCap (bottom panel) cells were incubated under normoxia and 1% hypoxia with equivalent doses of 
Cu(TPZ)2 and TPZ, and IC50 values were determined after 48, 72 and 96 h of incubation; B) Heat map of the hypoxia 
cytotoxicity ratio (HCR) values obtained for TPZ and Cu(TPZ)2 in the two PCa cell lines studied above. The IC50 values for 
inhibition were assessed by the resazurin assay and determined by nonlinear regression analysis of the data fit to a four-
parameter equation (GraphPad Prism version 7.0, GraphPad Software Inc., La Jolla, CA, USA) and used to calculate HCR: IC50 
normoxia/IC50 hypoxia. Results are expressed as mean ± SD for six replicates of at least three independent experiments (n>3). 
Statistical analysis: Two-way ANOVA multiple comparison Bonferroni Post-hoc test (***p≤0.001 and ****p≤0.0001, 
comparing normoxia vs hypoxia; #p≤0.05, ###p≤0.001 and ####p≤0.0001, comparing Cu(TPZ)2 vs TPZ).
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Figure 5. In vitro toxicity of Cu(TPZ)2 in C4-2B spheroids and DNA binding assay. A) fluorescent images of 3D C4-2B 
spheroids (day 5) incubated with CYTO-ID® Hypoxia Detection probe (500 nM, Enzo Life Sciences. UK) for 4 h, taken using an 
inverted Zeiss Axiovert 200M with Texas Red (596/670 nm) filter and equipped with a Zeiss ApoTome (Carl Zeiss, UK) to 
create optical sections free of scattered light. For each spheroid, a Ζ-stack with 10 µm thickness was generated. Scale bar: 
100 μm. IC50 curves of B) TPZ and C) Cu(TPZ)2 in C4-2B spheroids. 5 days post seeding, tumor spheroids were incubated with 
equivalent doses of Cu(TPZ)2 and TPZ, and IC50values were determined after 48, 72 and 96 h. Cell viability was assessed by the 
resazurin assay, with spheroids pre-treated for 30 min with EDTA (5 mM). Results were normalized to untreated and 
expressed as mean ± SD for six replicates of at least two independent experiments (n≥2). The IC50 values for inhibition were 
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determined by nonlinear regression analysis of the data fit to a four-parameter equation (GraphPad Prism version 7.0, 
GraphPad Software Inc., La Jolla, CA, USA). C4-2B spheroids were cultured for 5 days, then treated for 72 h with 20 and 2 µM 
equivalent TPZ in both free and complex forms and analyzed for D) cell cycle distribution and E) the percentage of apoptotic 
cells.  Each flow cytometry plot depicts the mean ± SD percentage of G1 (2n), S and G2/M (4n) fraction population. The data 
represents the mean of at least ten pooled spheroids of two independent experiments (n=2). F) Absorption spectra of the 
TPZ (50 µM) in the absence (dashed line) and presence (solid line) of increasing amounts of CT-DNA at room temperature in 5 
mM Tris/HCl/50 mM NaCl buffer, PH 7.2. Inset shows a zoom in of the visible spectral region, showing no changes in the 
spectrum. G) Absorption spectra of the complex (25 µM) in the absence (dashed line) and presence (solid line) of increasing 
amounts of CT-DNA at room temperature in 5 mM Tris/HCl/50 mM NaCl buffer, pH 7.2. The arrow depicts the absorbance 
spectrum changes on increasing the CT-DNA concentration. Inset shows the plot of [DNA]/(εa-εf) / (εb-εf) vs [DNA] and 
derived Κb value (M-1); Statistical analysis: Two-way ANOVA multiple comparison Bonferroni Post-hoc test (*p<0.05 **p<0.01, 
compared to control and #p<0.05 ##p<0.01, comparing TPZ vs Cu(TPZ)2, GraphPad Prism version 7.0).
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